The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
The approval of the SC formulation for this patient population was based on data from the JIGSAW-118 study, a 52-week, open-label, multicenter, pharmacokinetic (PK)/pharmacodynamic (PD) study. The ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ ...
The FDA approval of the ACTPen was supported by data from 2 studies: an open-label, randomized, 2-period, crossover Phase 1 study (N=188), and an open-label, non-randomized, observational Phase 4 ...
The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
As with other drugs, Actemra can cause side effects, such as weight gain, headache, and injection site reactions. Actemra has a boxed waring about the risk of serious infections. Be sure to talk with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results